Pharma Mar (PHMMF) Expected to Announce Quarterly Earnings on Thursday

Pharma Mar (OTCMKTS:PHMMF) is expected to be posting its resultson Thursday, April 23rd. Analysts expect Pharma Mar to post earnings of $0.2789 per share and revenue of $43.1330 million for the quarter.

Pharma Mar Stock Performance

PHMMF stock opened at $106.48 on Thursday. The company has a fifty day moving average price of $92.62 and a 200-day moving average price of $91.30. The company has a quick ratio of 2.44, a current ratio of 3.02 and a debt-to-equity ratio of 0.14. Pharma Mar has a 52-week low of $80.91 and a 52-week high of $110.40.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.